XNK04 / XNK Therap - LARVOL DELTA

XNK Therapeutics Enters into Research Agreement with Global Pharma Company (PRNewswire) - "XNK Therapeutics AB...announced that the company's autologous natural killer (NK) cell therapy candidate XNK04 will be evaluated in combination with an ADCC competent PD-L1 inhibitor in liver cancer under a research agreement with a global pharma company. The preclinical validation study aims to test the cell therapy candidate XNK04 alone and in combination with an antibody checkpoint inhibitor against autologous cancer cells isolated from patients with hepatocellular carcinoma (HCC). The study will provide data to support initiation of a potential future clinical phase I/II trial."

Licensing / partnership • Preclinical • Gastrointestinal Cancer • Hepatocellular Cancer • Liver Cancer • Oncology • Solid Tumor